September 9, 2022 – WizeCare, a health technology company providing enterprise-wide virtual physical rehabilitation and remote monitoring solutions for healthcare providers, announced today it has entered into a know-how and research agreement with Mayo Clinic to collaborate on the development of a home-based cardiac rehabilitation program.
The new program aims to set a new standard of care by harnessing Mayo Clinic’s know-how with WizeCare’s groundbreaking AI-driven technology to advance remote cardiac rehabilitation monitoring capabilities for better adherence and improved patient outcomes. WizeCare’s cloud-based solution consists of an interactive patient application that delivers virtual reality video sessions while using MoveAI™ technology to detect movement and provide real-time feedback for an intuitive, personalized and engaging rehabilitation experience.
Today, the current standard of care in cardiac rehabilitation monitors blood pressure and heart rate during a face-to-face visit, with only age, gender and a few other factors remotely monitored.
The new program will leverage WizeCare’s AI-driven technology to automate and guide patients in their daily exercise training, as well as monitor for the first time multiple new parameters remotely. This will include heart rate, cardiopulmonary fitness level, oxygen consumption, walking performance and other known relevant factors. Patients will also receive educational videos, feedback, and reinforcement to help improve lifestyle behaviors.
With improved remote tools and greater patient insight, the program will support practitioners to identify life-threatening cardiac events earlier and better tailor rehabilitation exercises to patient’s needs for improved safety, adherence, and outcomes.
Future program developments will also look to integrate blood pressure, sleep, and physical activity monitoring with automated alerts in response to abnormal events to further support clinical decision making and optimization of treatment plans.
The know-how is being provided by Dr. Amir Lerman, Associate Chair of the Department of Cardiovascular Medicine and the Director of the Cardiovascular Research Center at Mayo Clinic and Dr. Francisco Lopez-Jimenez, a Professor of Medicine at Mayo College of Medicine and the chair of the Division of Preventive Cardiology at Mayo Clinic.